For decades, a pancreatic cancer diagnosis at an advanced stage was effectively a death sentence. The five-year survival rate for metastatic pancreatic cancer — the form most patients have when diagnosed, because the cancer causes no early symptoms — sits below 3%. Chemotherapy offered modest survival extensions measured in weeks or a few months. Immunotherapy largely failed. The cancer was driven by a mutated gene called KRAS, which researchers called "undruggable" because they could not find a way to target it with medication.
That era may now be ending. A landmark Phase 3 clinical trial of a new drug called daraxonrasib, presented at the American Society of Clinical Oncology Annual Meeting in June 2026, found that patients with metastatic pancreatic cancer who received daraxonrasib lived a median of 13.2 months — compared to 6.7 months for those who received standard chemotherapy. That is not an incremental improvement. It is a near-doubling of survival time in one of medicine's most lethal diseases, and it represents the most significant advance in pancreatic cancer treatment in decades. Researchers at the meeting responded with a rare standing ovation.
